The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
Vandana VeenitHiddo J Lambers HeerspinkChristine AhlstromPeter J GreasleyStanko SkriticNatalie van ZuydamDonald E KohanPernille B L HansenRobert I MenziesPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
Combining ETARA with SGLT2i prevents ETARA induced fluid retention, supporting clinical studies to assess the efficacy and safety of combining zibotentan and dapagliflozin in individuals with CKD.